JWATM 203
Alternative Names: JWATM-203Latest Information Update: 18 Aug 2023
At a glance
- Originator Eureka Therapeutics
- Developer Eureka Therapeutics; JW Therapeutics
- Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Liver cancer
Most Recent Events
- 18 Aug 2023 Phase-I/II clinical trials in Liver cancer in USA (Parenteral)before August 2023 (JW Therapeutics pipeline, August 2023)
- 31 Dec 2020 Preclinical trials in Liver cancer in USA (unspecified route)
- 31 Dec 2020 Eureka therapeutics files an IND application with the FDA in USA for liver cancer prior to December 2020